CSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

Journal of Neural Transmission

Volumn 107, Issue 5, 2000, Pages 563-579

  Sjogren M ^a   Minthon, L ^b   Davidsson, P ^a   Granerus A K ^c   Clarberg, A ^b   Vanderstichele, H ^d   Vanmechelen, E ^d   Wallin, A ^a   Blennow, K ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c University of Health Sciences   (Sweden)

^d INNOGENETICS   (Belgium)

Author keywords

Alzheimer's disease; Biochemical marker; Cerebrospinal fluid; Frontotemporal dementia; GAP 43; Parkinson's disease; Subcortical; Tau; Vascular dementia; White matter; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; NEUROMODULIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DEMENTIA; DYSTHYMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; WHITE MATTER;

EID: 0034060813     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020070079     Document Type: Article

References (61)

1. Altman DG (1997) Practical statistics for medical research. Chapman and Hall, London
2. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised. American Psychiatric Association, Washington
3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
4. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, Raiha I, Sourander L, Winblad B, Blennow K (1998) Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry 64: 298-305
5. Andreasen N, Blennow K, Sjodin C, Winblad B, Svardsudd K (1999a) Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Pitea dementia project. Neuroepidemiology 18: 144-155
6. Andreasen N, Hesse C, Davidsson P, Wallin A, Minthon L, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999b) Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer's disease: differences between early-and late-onset AD and stability during the course of disease. Arch Neurol 56: 673-680
7. Arai H, Terajima M, Miura M, Higuchi S, Muramarsu T, Machida N, Seki H, Takase S, Clark CM, Lee VM-Y, Trojanowski JQ, Sasaki H (1995) Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 38: 649-652
8. Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, Miura M, Machida N, Lee VM, Trojanowski JQ, Sasaki H (1997) Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 236: 262-264
9. Arai H, Satoh-Nakagawa T, Higuchi M, Morikawa Y, Miura M, Kawakami H, Seki H, Takase S, Sasaki H (1998) No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci Lett 256: 174-176
10. Basi GS (1987) Primary structure and transcriptional regulation of GAP-43, a protein associated with nerve growth. Cell 49: 785-791
11. Blennow K, Fredman P, Wallin A, Gottfries C-G, Langstrom L, Svennerholm L (1993) Protein analysis in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur Neurol 33: 126-128
12. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26: 231-245
13. Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P (1996) Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm [Gen Sect] 103: 603-618
14. Bogdanovic N, Davidsson P, Volkmann I, Winblad B, Blennow K (2000) Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer's disease: a quantitative and immunohistochemical study. J Neural Transm 107: 463-478
15. Brun A (1993) Frontal lobe degeneration of non-Alzheimer type revisited. Dementia 4: 126-131
16. Brun A, Englund B, Gustafsson L, Passant U, Mann DMA, Neary D, Snowden JS (1994) clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 57: 416-418
17. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R (1992) Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 42: 473-480
18. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3: 67-72
19. Coleman PD, Kazee AM, Lapham L, Eskin T, Rogers K (1992) Reduced GAP-43 message levels are associated with increased neurofibrillary tangle density in the frontal association cortex (area 9) in Alzheimer's disease. Neurobiol Aging 13: 631-639
20. Davidsson P, Blennow K (1998) Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr 10: 11-23
21. Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K (1996) Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer's disease? Mol Chem Neuropathol 27: 195-210
22. De la Monte SM, Federoff HJ, Ng SC, Grabczyk E, Fishman MC (1989) GAP-43 gene expression during development: persistence in a distinctive set of neurons in the mature central nervous system. Brain Res Dev Brain Res 46: 161-168
23. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with disease severity. Ann Neurol 27: 457-464
24. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state", A practical method for grading the cognitive state of patients for the clinician. J Psychol Res 12: 189-198
25. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55: 937-945
26. Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 16: 460-465
27. Green AJ, Harvey RJ, Thompson EJ, Rossor MN (1999) Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett 259: 133-135
28. Gustafson L, Abrahamson M, Grubb A, Nilsson K, Fex G (1997) Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord 8: 240-243
29. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Heutink P, et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393: 702-705
30. Jellinger KA (1996) Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol 91: 219-220
31. Jensen M, Basun H, Lannfelt L (1995) Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 186: 189-191
32. Kane JW, Gowland E (1986) A method for the identification of apolipoprotein E isoforms employing chemical precipitation and flat bed isoelectric focusing in agarose. Ann Clin Biochem 23: 509-513
33. Knopman DS (1993) Overview of dementia lacking distinctive histology: pathological designation of a progressive dementia. Dementia 4: 132-136
34. Kosunen O, Soininen H, Paljärvi L, Heinonen O, Talasniemi S, Riekkinene PJS (1996) Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol 91: 185-193
35. Liu X, Brun A (1996) Regional and laminar synaptic pathology in frontal lobe degeneration of non-Alzheimer type. Int J Geriatr Psych 11: 47-55
36. Masliah E, Mallory M, Hansen L, Alford M, Albright T, DeTeresa R, Terry R, Baudier J, Saitoh T (1991) Patterns of aberrant sprouting in Alzheimer's disease. Neuron 6: 729-739
37. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944
38. Mecocci P, Cherubini A, Bregnocchi M, Chionne F, Cecchetti R, Lowenthal DT, Senin U (1998) Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? Alzheimer Dis Assoc Disord 12: 211-214
39. Minthon L, Hesse C, Sjogren M, Englund E, Gustafson L, Blennow K (1997) The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. Neurosci Lett 226: 65-67
40. Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R, Usami M, Shoji M, Maruyama S, Hirai S (1995) Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 186: 181-183
41. Motter R, Vigo Pelfrey C, Kholodenko D, Barbour R, Johnson Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, et al. (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38: 643-648
42. Neary D (1990) Dementia of frontal lobe type. J Am Geriatr Soc 38: 71-72
43. Risberg J, Gustafson L (1983) 133Xe cerebral blood flow in dementia and in neuropsychiatry research. In: Magistretti PL (ed) Functional radionuclide imaging of the brain. Raven Press, New York, pp 151-159
44. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Moody DM, O'Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennett DA, Fisher M, Ogata J, Kokmen E, Bermejo F, Wolf PA, Gorelick PB, Bick KL, Pajeau AK, Bell MA, DeCarli C, Culebras A, Korczyn AD, Bogousslavsky J, Hartmann A, Scheinberg P (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International workshop. Neurology 43: 250-260
45. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group (1998) Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol Aging 19: 109-116
46. Roses AD, Saunders AM (1994) APOE is a major susceptibility gene for Alzheimer's disease. Curr Opin Biotechnol 5: 663-667
47. Sjögren M, Edman Å, Wallin A (1997) Symptomatological characteristics distinguish between frontotemporal dementia and vascular dementia with a dominating frontal lobe syndrome. Int J Geriatr Psychiatry 12: 656-661
48. Skene JH, Willard M (1981) Characteristics of growth-associated polypeptides in regenerating toad retinal ganglion cell axons. J Neurosci 1: 419-426
49. Skoog I, Vanmechelen E, Andreasson LA, Palmertz B, Davidsson P, Hesse C, Blennow K (1995) A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 4: 433-442
50. Tamaoka A, Sawamura N, Odaka A, Suzuki N, Mizusawa H, Shoji S, Mori H (1995) Amyloid beta protein 1-42/43 (A beta 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study. Brain Res 679: 151-156
51. Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, Alafuzoff I, Riekkinen P Sr, Soininen H (1997) The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 8: 3961-3963
52. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580
53. Tibbling G, Link H, Ohman S (1977) Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 37: 385-390
54. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P (1993) Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 61: 1828-1834
55. Vanderstichele H, Blennow K, D'Heuvaert N, Buyse M, Wallin A, Andreasen N, Seubert P, Van De Voorde A, Vanmechelen E (1998) Development of a specific diagnostic test for measurement of b-amyloid (1-42) in CSF. In: Fisher A, Hanin I, Yoshida M (eds) Progress in Alzheimer's and Parkinson's diseases. Plenum Press, New York, pp 773-778
56. Vanmechelen E, Blennow K, Davidsson P, Cras P, Vand de Voorde A (1997) Combination of tau/phospho-tau with other biochemical markers for Alzheimer CSF diagnosis and tau in CSF as marker for neurodegeneration. In: Iqbal K, Winblad B, Nishimuta T, Takeda M, Wisniewski HM (eds) Alzheimer's disease: biology, diagnosis and therapeutics. John Wiley & Sons, Chichester, pp 197-203
57. Vermersch P, Bordet R, Ledoze F, Ruchoux MM, Chapon F, Thomas P, Destee A, Lechevallier B, Delacourte A (1995) Demonstration of a specific profile of pathological tau proteins in frontotemporal dementia cases. CR Acad Sci 318: 439-445
58. Wallin A, Blennow K, Gottfries C-G (1991) Subcortical symptoms predominate in vascular dementia. Int J Geriatr Psychiatry 6: 137-145
59. Wallin A, Brun A, Gustafson L (1994) Swedish consensus on dementia diseases. Acta Neurol Scand 90: 8-18
60. Wallin A, Jennersjo, C, Granérus A-K (1999) Prevalence of dementia and regional brain syndromes in long-standing Parkinson's disease. Parkinsonism Rel Dis 5: 103-110
61. Yam PS, Takasago T, Dewar D, Graham DI, McCulloch J (1997) Amyloid precursor protein accumulates in white matter at the margin of a focal ischaemic lesion. Brain Res 760: 150-157